Provided by Tiger Trade Technology Pte. Ltd.

Compass Therapeutics, Inc.

0.9834
-0.0366-3.59%
Post-market: 0.98340.00000.00%16:10 EDT
Volume:7.04M
Turnover:6.90M
Market Cap:177.10M
PE:-2.43
High:1.01
Open:1.01
Low:0.9573
Close:1.02
52wk High:6.88
52wk Low:0.8294
Shares:180.09M
Float Shares:132.00M
Volume Ratio:0.62
T/O Rate:5.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4039
EPS(LYR):-0.4216
ROE:-56.66%
ROA:-33.03%
PB:1.07
PE(LYR):-2.33

Loading ...

Compass Therapeutics sets Delaware, Massachusetts federal courts as exclusive venue for Securities Act claims

Reuters
·
Jun 23

Compass Therapeutics Shareholders Back Directors, Pay, Auditor Oversight

TIPRANKS
·
Jun 12

Compass Therapeutics shareholders elect Schuetz, Lindahl to board

Reuters
·
Jun 12

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Compass Therapeutics (CMPX) and Tenax Therapeutics (TENX)

TIPRANKS
·
Jun 01

Compass Therapeutics to Participate in Upcoming June Investor Events

GlobeNewswire
·
May 28

Compass Therapeutics reports Phase 1 CTX-8371 data showing 33% ORR at top doses

Reuters
·
May 22

Compass Therapeutics to Participate in Upcoming May Investor Events

GlobeNewswire
·
May 12

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH), Tenax Therapeutics (TENX) and Compass Therapeutics (CMPX)

TIPRANKS
·
May 10

Compass Therapeutics Inc. reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 06

Guggenheim Remains a Buy on Compass Therapeutics (CMPX)

TIPRANKS
·
May 06

Compass Therapeutics Inc. : Leerink Partners Cuts Target Price to $4 From $11

THOMSON REUTERS
·
May 06

Compass Therapeutics: Buy Rating Reiterated as Clinical Progress Strengthens Approval Odds; $6 Price Target Maintained

TIPRANKS
·
May 06

H.C. Wainwright Keeps Their Buy Rating on Compass Therapeutics (CMPX)

TIPRANKS
·
May 05

Compass Therapeutics Q1 EPS $(0.10), Inline

Benzinga Earnings
·
May 05

Compass Therapeutics Q1 net loss widens on higher R&D, G&A costs

Reuters
·
May 05

Press Release: Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update

Dow Jones
·
May 05

Compass Therapeutics announces annual shareholder meeting webcast

Reuters
·
Apr 29

Compass Therapeutics Price Target Maintained With a $10.00/Share by Citizens

Dow Jones
·
Apr 28

Compass Therapeutics announces annual shareholder meeting webcast

Reuters
·
Apr 28

Compass Therapeutics publishes 2025 annual report

Reuters
·
Apr 28